Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 47.74$. Average daily volumn in 3 months 2.5M. Market cap 121.13B



Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD
Lastest price : 47.71$. Total volume : 2.26M. Market state POST
Click reload if you want to check the lastest price on market!!!

Sanofi (SNY)
Last Price
47.71$
Change
0.74
Volume
2.26M

Previous Close46.97
Open47.70
Day Range47.44-47.80
Bid45.93 x 900
Ask47.81 x 1.2k
Volume2.26M
Average Volume2.5M
Market Cap121.13B
Beta0.41
52 Week Range36.91-58.10
Trailing P/E16.45
Foward P/E9.58
Dividend (Yield %)3.81%
Ex-Dividend Date2022-05-26



Financial Details


According to Sanofi's financial reports the company's revenue in 2022 were 45.39B an increase( +15.38%) over the years 2021 revenue that were of 39.17B. In 2022 the company's total earnings were 6.72B while total earnings in 2021 were 6.22B(0%).


Loading ...



Organization

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Market Cap:
121.13B
Revenue:
45.39B
Total Assets:
124.58B
Total Cash:
12.74B


News about "Sanofi"

sanofi-renews-social-campaign-to-remind-that-vaccines-let-people-dream-big-image

Sanofi re­news so­cial cam­paign to re­mind that vac­cines let peo­ple ‘Dream Big’

Source from : ENDPOINTS NEWS - 11 hours ago

Sanofi is highlighting people's dreams — both big and small — to make the point that vaccines make them possible. The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teach ...See details»


sanofi-nasdaqsny-q4-2022-earnings-call-transcript-image

Sanofi (NASDAQ:SNY) Q4 2022 Earnings Call Transcript

Source from : Yahoo - 17 hours ago

Sanofi (NASDAQ:SNY) Q4 2022 Earnings Call Transcript February 3, 2023 Eva Schaefer-Jansen: find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to slide 3, ...See details»


sanofi-forecasts-moderate-profit-growth-on-dupixent-demand-image

Sanofi forecasts moderate profit growth on Dupixent demand

Source from : Reuters on MSN - 5 days ago

Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis ...See details»


sanofi-stock-dips-as-q4-revenue-grows-but-vaccine-sales-fall-dupixent-drives-moderate-profit-outlook-image

Sanofi stock dips as Q4 revenue grows but vaccine sales fall; Dupixent drives moderate profit outlook

Source from : Seeking Alpha on MSN - 5 days ago

Q4 sales grow on the back of blockbuster drug Dupixent but Vaccines business sees decline.The French pharma giant also provided FY23 outlook.Q4 Business EPS rose ...See details»


Sanofi: Increasing Our Long Position

Source from : Seeking Alpha - 5 days ago

Sanofi delivered a good set of numbers and Dupixent is well on track with our estimates. Click here to read our analysis why we think the stock is a buy.See details»


sanofi-profit-narrowly-beats-forecasts-sees-stronger-earnings-growth-in-2023-image

Sanofi profit narrowly beats forecasts, sees stronger earnings growth in 2023

Source from : MarketWatch on MSN - 6 days ago

DOW JONES NEWSWIRES Sanofi SA on Friday posted rising earnings and sales for the fourth quarter and said it expects its earnings per share to grow in 2023. The French pharma major ...See details»


Sanofi Drops as Generic Competition to Weigh on Profit

Source from : Bloomberg L.P. - 6 days ago

Sanofi declined to the lowest in more than two months after the French drugmaker forecast a slowdown in profit growth as generic competition ratchets up for multiple sclerosis drug Aubagio.See details»


Sanofi to let go of staff at vaccine plants in India as part of review

Source from : Yahoo News - 9 days ago

(Reuters) - French drugmaker Sanofi SA is reviewing operations at two of its vaccine making facilities in India and plans to let go of all employees at the plants, the company told Reuters, after it ...See details»


Sanofi Forecasts Lower Earnings Growth In 2023

Source from : Barron's - 5 days ago

French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.See details»


Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare

Source from : Yahoo - 19 days ago

PARIS, Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53 rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher ...See details»


Sanofi picks Thread as sole provider of decentralized clinical trials for patient-focused platform

Source from : Outsourcing-pharma - 9 days ago

Thread is one of a number of companies that are trying to address persistent problems with clinical trials such as recruitment and retention through DCT platforms that loosen, and for some programs ...See details»


Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M

Source from : Benzinga.com - 28 days ago

Fund focuses on early stage investing, company co-creation, leading financing rounds and is committed to continuing its investment reach by prioritizing companies advancing innovation Sanofi ...See details»


Sanofi Upbeat on 2023 Earnings After 4Q Growth; Raises Dividend — Update

Source from : Morningstar%2c Inc. - 5 days ago

Sanofi SA on Friday posted rising earnings and sales for the fourth quarter, said it expects its earnings per share to grow in 2023, and raised its dividend for the year. The French pharma major ...See details»


Sanofi ADR

Source from : Wall Street Journal - 2 years ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»